Screening and optimization of phage display cyclic peptides against the WDR5 WBM site.
Lingyu SongJiawen CaoLin ChenZhiyan DuNaixia ZhangDanyan CaoBing XiongPublished in: RSC medicinal chemistry (2023)
Of the various WD40 family proteins, WDR5 is a particularly important multifunctional adaptor protein that can bind to several protein complexes to regulate gene activation, so it was considered as a promising epigenetic target in anti-cancer drug development. Despite many inhibitors having been discovered directing against the arginine-binding cavity in WDR5 called the WIN site, the side hydrophobic cavity called the WBM site receives rather scant attention. Herein, we aim to obtain novel WBM-targeted peptidic inhibitors with high potency and selectivity. We employed two improved biopanning approaches with a disulfide-constrained cyclic peptide phage library containing 7 randomized residues and identified several peptides with micromole binding activity by docking and binding assay. To further optimize the stability and activity, 9 thiol-reactive chemical linkers were utilized in the cyclization of the candidate peptide DH226027, which had good binding affinity. This study provides an effective method to discover potent peptides targeting protein-protein interactions and highlights a broader perspective of peptide-mimic drugs.
Keyphrases
- amino acid
- binding protein
- cancer therapy
- protein protein
- pseudomonas aeruginosa
- dna binding
- nitric oxide
- gene expression
- randomized controlled trial
- dna methylation
- open label
- molecular dynamics
- high throughput
- double blind
- genome wide
- molecular dynamics simulations
- small molecule
- ionic liquid
- placebo controlled
- study protocol
- phase iii
- single cell